← All trials
NCT04729517
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2021
- Primary completion
- Dec 1, 2021
- Completion date
- Feb 15, 2022
- First posted
- Jan 28, 2021
- Last posted
- May 13, 2021
- Enrollment
- 264
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Abdi Ibrahim PharmaceuticalsLead sponsor
- Uludag UniversityCollaborator
- Antalya Training and Govermental HospitalCollaborator
- Istanbul UniversityCollaborator
- University of AnkaraCollaborator
- Istanbul UniversityCollaborator
- Dokuz Eylul UniversityCollaborator
- Firat UniversityCollaborator
- Kahramanmaras Sutcu Imam UniversityCollaborator
- Ankara Yildirim Beyazıt UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.